
An International Publisher for Academic and Scientific Journals
Author Login
Scholars Academic Journal of Pharmacy | Volume-14 | Issue-03 Call for paper
Effect of Metformin on Lipid Profiles of T2DM Mellitus
Widad Ziad Yousef Mouasher, Bara’ah Ahmad Awad Alqura’an, Azhour Feras Fawaz Alhawamdeh, Oraib Jehad Hussein Alraggad, Hadeel Hamdi Hasan Abu Aisheh
Published: March 4, 2025 |
96
49
DOI: https://doi.org/10.36347/sajp.2025.v14i03.001
Pages: 37-41
Downloads
Abstract
Introduction: T2DM mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, leading to deregulated blood glucose levels and associated metabolic abnormalities. The standard management of T2DM includes pharmacological interventions, such as metformin, and lifestyle modifications like dietary changes. Metformin is widely prescribed for its glucose-lowering effects and potential benefits on lipid profiles. Dietary interventions, particularly those emphasizing low glycemic index foods and reduced saturated fat intake, are also critical in managing metabolic parameters in T2DM. Despite the known benefits of both interventions, limited data is available on their combined effects on haemoglobin levels, cholesterol, and triglycerides in real-world settings. This study aims to retrospectively evaluate the effects of metformin and dietary patterns on haemoglobin, cholesterol, and triglyceride levels in T2DM patients by analysing existing medical records. Methodology: A retrospective cohort study was conducted at the internal medicine department at King Hussein Medical Centre in The Royal Medical Services, Amman, Jordan. The study was conducted by obtaining Data for haemoglobin, cholesterol, and triglyceride levels from electronic medical records (Hakeem) of 200 T2DM patients who attended the outpatient diabetes clinic. Laboratory results were obtained from June 2024 to December 2024. Patients were divided to two groups: T2DM group used metformin without diet (group I) and a T2DM group also used metformin but with diet (group II). The parameters were assessed at day 0, after 3 months and after 6 months of treatment with metformin. Hb, TC and TGs, were measured. Results: There was a significant (p<0.05) drop in the Hb concentration in the blood between group I and group II, according to the results. Data analysis revealed that group I had a significantly higher cholesterol level. The results of the statistical analysis indicated that group I and ...